期刊
PROSTAGLANDINS & OTHER LIPID MEDIATORS
卷 91, 期 3-4, 页码 130-138出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.prostaglandins.2009.02.002
关键词
Lysophospholipids; LPA; S1P; GPCRs; Receptors; Autotaxin; LPP; PRG
资金
- National Institutes of Health (NIH) [MH051699, NS048478, HD050685]
Lysophosphatidic acid (LPA), a water-soluble phospholipid, has gained significant attention in recent years since the discovery that it acts as a potent signaling molecule with wide-ranging effects on many different target tissues. There are currently five identified G protein-coupled receptors for LPA and more are undergoing validation. The complexity of the expression pattern and signaling properties of LPA receptors results in multiple influences on developmental, physiological, and pathological processes. This review provides a summary of LPA receptor signaling and current views on the potential involvement of this pathway in human diseases that include cardiovascular, cancer, neuropathic pain, neuropsychiatric disorders, reproductive disorders, and fibrosis. The involvement of LPA signaling in these processes implicates multiple, potential drug targets including LPA receptor subtypes and LPA metabolizing enzymes. Modulation of LPA signaling may thus provide therapeutic inroads for the treatment of human disease. (C) 2009 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据